Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502

PURPOSE: The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Attar, Eyal C., Johnson, Jeffrey L., Amrein, Philip C., Lozanski, Gerard, Wadleigh, Martha, DeAngelo, Daniel J., Kolitz, Jonathan E., Powell, Bayard L., Voorhees, Peter, Wang, Eunice S., Blum, William, Stone, Richard M., Marcucci, Guido, Bloomfield, Clara D., Moser, Barry, Larson, Richard A.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2013
Matèries:
Original Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577952/
https://ncbi.nlm.nih.gov/pubmed/23129738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.45.2177
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars